Related Experiment Video
Updated: Feb 24, 2026
06:19
Chinese Herbal Retention Enema for the Treatment of Ulcerative Colitis
Published on: May 16, 2025
1.7K
Curcumin-QingDai Combination for Active Ulcerative Colitis: A Cost-Effectiveness Analysis
Henit Yanai1, David Choi2, Shomron Ben-Horin3
1Division of Gastroenterology, Rabin Medical Center, Petah Tikva, Israel; Gray Faculty of Medical and Health Sciences, Tel Aviv University, Tel Aviv, Israel.
Summary
Curcumin and QingDai (CurQD) offers a cost-effective treatment for ulcerative colitis (UC) compared to advanced therapies. This nutraceutical provides significant benefits, making it a valuable option for patients with active UC.
Area of Science:
- Gastroenterology
- Pharmacoeconomics
- Integrative Medicine
Background:
- Active ulcerative colitis (UC) treatment often involves advanced therapies.
- Curcumin and QingDai (CurQD), a herbal compound, shows promise for UC management.
- No prior cost-effectiveness analysis exists for CurQD in UC treatment.
Purpose of the Study:
- To evaluate the cost-effectiveness of CurQD compared to current advanced therapies for moderate-to-severe UC.
- To analyze cost-effectiveness for both advanced therapy-naïve and experienced UC patient cohorts.
Main Methods:
- A Markov model simulated UC patient progression over 54 weeks.
- Efficacy data synthesized from randomized controlled trials and real-world studies.
- Cost data based on US average wholesale price; $50,000/QALY threshold used.
Main Results:
- CurQD demonstrated an incremental cost-effectiveness ratio (ICER) exceeding $200,000/QALY against advanced therapies.
- Quality-adjusted life year (QALY) differences were marginal, ranging from -0.1 to 0.07.
- Sensitivity analysis confirmed the robustness of the findings.
Conclusions:
- CurQD presents a significantly cost-effective alternative to advanced UC therapies.
- The reduced cost and proven efficacy of CurQD offer a compelling benefit.
- This includes cost-effectiveness over anti-TNF biosimilars for active UC.
More Related Videos
Related Concept Videos
01:29Drugs for Treatment of Ulcerative Colitis in IBD
565
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
565
01:24Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents
1.7K
In the intricate landscape of the gastric lumen, excessive acid secretion disrupts the natural defense mechanisms, weakening the mucus-bicarbonate barrier. This vulnerability allows pepsin to infiltrate epithelial cells, digesting mucosal proteins and triggering erosion, leading to ulcer formation.
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
1.7K
01:20Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
1.3K
The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
1.3K
01:26Peptic Ulcer Disease IV: Management
555
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
555
01:21Drugs for Treatment of Constipation-Predominant IBS
959
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
959
01:29Inflammatory Bowel Disease IV: Pharmacological Management
837
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
837